Company profilePharmaceutical#130 of 1,318 in Pakistan✓ No DRAP alerts

Martin Dow Marker Limited

Pharmaceutical company · 133 brands · 115 molecules

Ranked #58 of 112 companies in Blood Glucose Lowering Drugs, Excluding Insulin

133 registered products 55 pharmaceutical brands 115 distinct molecules 0 DRAP alerts

Company overview

133
registered products
55
pharmaceutical brands
115
distinct molecules
12
therapeutic classes
0
DRAP alerts

Martin Dow Marker Limited is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 133 product registrations across 115 distinct molecules. It is the 130th largest registrant in Pakistan by product count, and ranks 58th of 112 in Blood Glucose Lowering Drugs, Excluding Insulin. Its portfolio is concentrated in Blood Glucose Lowering Drugs, Excluding Insulin and Anti-Infectives. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Martin

176 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

98
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
202698

Top molecules by brand count

Metformin8 brands
Risperidone5 brands
Ceftriaxone5 brands
Cefixime4 brands
Azithromycin3 brands
Gentamicin3 brands
Artemether3 brands

Therapeutic classes

Blood Glucose Lowering Drugs, Excluding Insulin · 2Anti-Infectives · 2Pain Management · 2Gonadotropins And Other Ovulation Stimulants · 2Tetracyclines · 1Antithrombotic Agents · 1Other Beta-Lactam, Cephalosporins & Penems · 1Antiinflammatory And Antirheumatic Products · 1Antispasmodic & Anticholinergic · 1Topical Products For Joint And Muscular Pain · 1Vitamin B1, & Combinations Of B1, B6, B12 · 1Beta Blocking Agent · 1

Conditions treated

General Infections · 2Pain Killers · 1Heart Failure · 1Oral Agents · 1Muscle Relaxant/Spasm · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official133 products · Rs 50.79 – Rs 304,900.15
DVAGO26 products · Rs 43.7 – Rs 1,143.6
Servaid13 products · Rs 118.5 – Rs 724
Median across source: Rs 214.56

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

HIGH - Q INTERNATIONAL30 shared molecules
NEUTRO PHARMA (PVT) LTD.30 shared molecules
AGP (PRIVATE) LTD.29 shared molecules
HILTON PHARMA (PVT) LIMITED28 shared molecules
SEARLE PAKISTAN (PVT.) LTD.28 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

GETZ PHARMA PAKISTAN (PVT) LTD. holds 224 molecules not in this portfolio
),Formoterol3 ) 20Mg} Folic AcidAcetazolamideAcyclovirAdrenalineAlbendazole
NABIQASIM INDUSTRIES (PVT) LTD. holds 151 molecules not in this portfolio
2 MiuAcefyllin PiperazineAcefyllineAcetaminophinAcetylsalicyclic AcidAcyclovir
HIGH - Q INTERNATIONAL holds 93 molecules not in this portfolio
Acetyl L-CarnitineAmikacinAnastrozoleAprepitantArachis OilAtorvastatin

Get the full profile for Martin

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.